Expression of Biomarkers Estrogen Receptor, Progesterone Receptor, HER2 in Primary Breast Tumour and Synchronous Metastatic Axillary Lymph Node
- 1 July 2021
- journal article
- research article
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
Abstract
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.Keywords
This publication has 9 references indexed in Scilit:
- Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastasesOncology Letters, 2020
- The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node MetastasisAsian Pacific Journal of Cancer Prevention, 2020
- Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodesIndian Journal of Cancer, 2020
- Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic DecisionApplied Immunohistochemistry & Molecular Morphology, 2018
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigationOncoTargets and Therapy, 2014
- Significance of immunohistochemistry in breast cancerWorld Journal of Clinical Oncology, 2014
- Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastasesAnnals of Oncology, 2010
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007